Bio-Rad Laboratories (BIO.B) Financials

$250.08 0.00 (0.00%)

As of 05/23/2025

Annual Income Statements for Bio-Rad Laboratories

This table shows Bio-Rad Laboratories' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Income / (Loss) Attributable to Common Shareholders	-1,844	-637	-3,628	4,254	3,814	1,759	366	122	26	109
Consolidated Net Income / (Loss)	-1,844	-637	-3,628	4,254	3,814	1,759	366	122	26	109
Net Income / (Loss) Continuing Operations	-1,844	-637	-3,628	4,254	3,814	1,759	366	122	26	109
Total Pre-Tax Income	-2,343	-850	-4,704	5,449	4,918	2,261	513	98	42	146
Total Operating Income	269	338	483	500	421	230	-103	119	56	167
Total Gross Profit	1,379	1,427	1,567	1,638	1,438	1,257	1,223	1,188	1,138	1,122
Total Revenue	2,567	2,671	2,802	2,923	2,546	2,312	2,289	2,160	2,068	2,019
Operating Revenue	2,567	2,671	2,802	2,923	2,546	2,312	2,289	2,160	2,068	2,019
Total Cost of Revenue	1,188	1,244	1,235	1,284	1,108	1,055	1,066	972	930	898
Operating Cost of Revenue	1,188	1,244	1,235	1,284	1,108	1,055	1,066	972	930	898
Total Operating Expenses	1,110	1,089	1,085	1,138	1,017	1,027	1,326	1,068	1,083	955
Selling, General & Admin Expense	814	842	828	877	799	825	835	807	815	762
Research & Development Expense	296	247	257	261	218	203	199	250	206	193
Total Other Income / (Expense), net	-2,612	-1,188	-5,187	4,949	4,497	2,031	616	-21	-14	-21
Interest Expense	49	49	38	1.55	22	23	24	23	23	22
Interest & Investment Income	-2,657	-1,252	-5,194	4,926	4,496	2,031	-	-	-	-
Other Income / (Expense), net	94	114	45	24	23	24	640	1.57	9.22	0.83
Income Tax Expense	-498	-213	-1,077	1,195	1,104	502	147	-24	16	37
Basic Earnings per Share	($65.36)	($21.82)	($121.79)	$142.61	$128.13	$58.93	$12.25	$4.12	$0.88	$3.74
Weighted Average Basic Shares Outstanding	28.21M	29.21M	29.79M	29.83M	29.77M	29.84M	29.84M	29.66M	29.44M	29.19M
Diluted Earnings per Share	$0.00	$0.00	$0.00	$140.83	$126.47	$58.27	$12.10	$4.07	$0.88	$3.71
Weighted Average Diluted Shares Outstanding	28.21M	29.21M	29.79M	30.21M	30.16M	30.18M	30.23M	30.03M	29.65M	29.41M
Weighted Average Basic & Diluted Shares Outstanding	28.01M	28.52M	29.60M	29.93M	29.84M	29.93M	29.80M	-	29.58M	29.36M

This table shows Bio-Rad Laboratories' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Income / (Loss) Attributable to Common Shareholders	64	-716	653	-2,165	384	350	106	-1,162	69	828	-163
Consolidated Net Income / (Loss)	64	-716	653	-2,165	384	350	106	-1,162	69	828	-163
Net Income / (Loss) Continuing Operations	64	-716	653	-2,165	384	350	106	-1,162	69	828	-163
Total Pre-Tax Income	83	-909	862	-2,786	491	428	137	-1,500	85	1,091	-207
Total Operating Income	24	58	64	101	45	95	91	90	62	119	95
Total Gross Profit	306	342	356	355	326	366	336	362	362	397	373
Total Revenue	585	667	650	638	611	681	632	681	677	730	681
Operating Revenue	585	667	650	638	611	681	632	681	677	730	681
Total Cost of Revenue	279	326	294	283	285	315	296	319	314	333	308
Operating Cost of Revenue	279	326	294	283	285	315	296	319	314	333	308
Total Operating Expenses	282	284	291	254	281	271	245	273	301	278	278
Selling, General & Admin Expense	209	204	200	195	215	207	201	208	226	212	211
Research & Development Expense	74	80	91	59	66	64	44	65	75	66	67
Total Other Income / (Expense), net	60	-967	797	-2,888	446	333	46	-1,590	23	973	-302
Interest Expense	12	12	12	12	12	12	12	12	12	12	12
Other Income / (Expense), net	72	1,702	809	-2,876	459	1,598	59	-1,578	35	6,178	-290
Income Tax Expense	19	-193	208	-621	107	79	31	-338	16	264	-45
Basic Earnings per Share	$2.29	($25.93)	$23.37	($76.26)	$13.46	$11.79	$3.65	($39.59)	$2.33	$27.24	($5.48)
Weighted Average Basic Shares Outstanding	27.94M	28.21M	27.95M	28.40M	28.52M	29.21M	29.10M	29.36M	29.60M	29.79M	29.73M
Diluted Earnings per Share	$2.29	$39.47	$23.34	($76.26)	$13.45	$33.63	$3.64	($39.59)	$2.32	$117.98	($5.48)
Weighted Average Diluted Shares Outstanding	27.96M	28.21M	27.99M	28.40M	28.54M	29.21M	29.22M	29.36M	29.75M	29.79M	29.73M
Weighted Average Basic & Diluted Shares Outstanding	27.21M	28.01M	28.00M	27.87M	28.52M	28.52M	29.15M	29.08M	29.61M	29.60M	29.82M

This table details how cash moves in and out of Bio-Rad Laboratories' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Net Change in Cash & Equivalents	85	-30	-216	-196	-618	-229	-229	-194	-1.65	44
Net Cash From Operating Activities	455	375	18	669	585	0.29	285	-18	216	0.74
Net Cash From Continuing Operating Activities	455	375	18	672	-25	0.29	7.60	-18	216	0.74
Net Income / (Loss) Continuing Operations	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Non-Cash Adjustments To Reconcile Net Income	435	367	18	672	-25	0.29	7.60	-18	-49	0.74
Changes in Operating Assets and Liabilities, net	20	8.20	-	-	-	-	-	-	265	-
Net Cash From Investing Activities	-160	20	-1,208	-797	-70	-209	-187	-176	-214	-167
Net Cash From Continuing Investing Activities	-137	20	-1,208	-797	-70	-209	-187	-176	-214	-167
Purchase of Property, Plant & Equipment	-166	-157	-113	-134	-109	-99	-130	-115	-141	-116
Acquisitions	0.00	0.00	-101	-126	-97	-79	0.00	-	-0.14	-1.37
Purchase of Investments	-1,277	-689	-2,060	-1,305	-248	-371	-371	-360	-293	-299
Sale of Property, Plant & Equipment	0.10	0.20	0.20	0.05	0.07	0.13	4.32	0.09	0.40	0.08
Divestitures	0.00	2.50	1.40	0.00	12	0.00	7.23	-	-	-
Sale and/or Maturity of Investments	1,305	863	1,066	767	368	332	302	300	220	249
Other Investing Activities, net	0.00	0.00	-1.50	0.00	3.41	8.82	-0.00	-	0.00	-
Net Cash From Financing Activities	-219	-426	974	-55	-523	-23	-49	0.34	9.02	8.58
Net Cash From Continuing Financing Activities	-219	-426	974	-55	-523	-23	-49	0.34	9.02	8.58
Repayment of Debt	-1.00	-0.50	-0.50	-3.02	-427	-1.13	-2.96	-0.35	-0.30	-0.28
Repurchase of Common Equity	-204	-429	-216	-50	-100	-28	-49	-2.92	0.00	0.00
Issuance of Common Equity	19	19	18	21	20	17	14	15	11	8.24
Other Financing Activities, net	-33	-15	-14	-23	-16	-11	-11	-11	-1.99	0.63

This table details how cash moves in and out of Bio-Rad Laboratories' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Net Change in Cash & Equivalents	-117	408	-128	-151	-43	247	-13	-198	-66	-128	-97
Net Cash From Operating Activities	-22	455	23	-23	0.00	375	24	-24	0.00	18	-
Net Cash From Continuing Operating Activities	-22	455	23	-23	0.00	375	24	-24	0.00	18	-
Net Income / (Loss) Continuing Operations	0.00	-	-	-	0.00	-	-	-	0.00	-	-
Non-Cash Adjustments To Reconcile Net Income	-22	-	-	-	-	-	-	-	-	-	-
Net Cash From Investing Activities	2.90	-31	-56	-31	-43	72	-9.50	28	-70	-59	-88
Net Cash From Continuing Investing Activities	2.90	-7.14	-56	-31	-43	72	-9.50	28	-70	-59	-88
Purchase of Property, Plant & Equipment	-34	-43	-40	-42	-40	-42	-44	-35	-36	-35	-28
Purchase of Investments	-153	-223	-399	-248	-406	-151	-196	-138	-204	-253	-329
Sale and/or Maturity of Investments	191	235	407	259	404	263	231	201	169	231	369
Net Cash From Financing Activities	-98	-26	-96	-97	0.02	-201	-27	-203	4.31	-87	-8.77
Net Cash From Continuing Financing Activities	-98	-26	-96	-97	0.02	-201	-27	-203	4.31	-87	-8.77
Repayment of Debt	-0.10	-0.02	-0.12	-0.12	-0.74	-0.15	-0.12	-0.12	-0.12	-0.13	-0.11
Repurchase of Common Equity	-102	-0.01	-98	-101	-4.75	-200	-21	-207	0.00	-91	-
Issuance of Common Equity	4.30	3.91	5.10	4.68	5.51	4.33	4.65	5.10	4.42	4.38	4.77

This table presents Bio-Rad Laboratories' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Total Assets	9,364	12,299	13,502	17,799	12,973	8,009	5,611	4,273	3,851	3,710
Total Current Assets	3,030	3,048	3,158	1,990	2,140	2,180	2,023	1,977	1,845	1,778
Cash & Equivalents	488	404	434	471	662	661	432	384	456	458
Restricted Cash	0.00	5.60	5.56	5.56	5.56	5.56	5.60	5.56	4.56	4.21
Short-Term Investments	1,176	1,203	1,356	399	329	454	413	371	383	329
Accounts Receivable	453	489	495	424	419	372	392	465	372	391
Inventories, net	760	781	719	572	622	554	584	595	525	490
Prepaid Expenses	123	140	124	109	91	102	187	146	91	94
Other Current Assets	31	26	24	10	11	11	9.62	10	12	11
Plant, Property, & Equipment, net	528	529	499	512	491	499	509	493	489	438
Total Noncurrent Assets	5,806	8,722	9,845	15,297	10,341	5,329	3,079	1,803	1,517	1,494
Long-Term Investments	4,839	7,698	8,831	14,387	9,561	4,638	2,656	1,028	831	720
Goodwill	411	414	406	347	292	264	220	506	477	496
Intangible Assets	294	321	332	254	199	146	133	174	162	214
Other Noncurrent Operating Assets	262	290	276	309	289	282	70	95	48	65
Total Liabilities & Shareholders' Equity	9,364	12,299	13,502	17,799	12,973	8,009	5,611	4,273	3,851	3,710
Total Liabilities	2,795	3,558	3,886	4,114	3,093	2,254	1,591	1,343	1,271	1,219
Total Current Liabilities	468	523	569	681	632	905	451	503	471	441
Short-Term Debt	1.20	0.50	0.47	0.49	1.80	426	0.49	0.42	0.33	0.30
Accounts Payable	122	145	135	142	139	107	122	135	133	122
Current Deferred & Payable Income Tax Liabilities	31	36	32	10	23	8.76	56	40	28	29
Current Employee Benefit Liabilities	124	140	195	277	223	180	144	172	163	158
Other Current Liabilities	189	202	206	164	168	122	101	127	115	102
Total Noncurrent Liabilities	2,327	3,035	3,318	3,433	2,461	1,348	1,140	840	800	778
Long-Term Debt	1,200	1,199	1,198	11	12	14	439	435	434	434
Noncurrent Deferred & Payable Income Tax Liabilities	818	1,476	1,770	3,065	2,077	998	553	222	225	233
Other Noncurrent Operating Liabilities	309	361	350	358	372	337	148	183	141	111
Commitments & Contingencies	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Total Equity & Noncontrolling Interests	6,569	8,741	9,615	13,685	9,880	5,755	4,020	2,930	2,579	2,491
Total Preferred & Common Equity	6,569	8,741	9,615	13,685	9,880	5,755	4,020	2,930	2,579	2,491
Preferred Stock	0.00	0.00	-	0.00	0.00	7.50	0.00	0.00	0.00	0.00
Total Common Equity	6,569	8,741	9,615	13,685	9,880	5,755	4,020	2,930	2,579	2,491
Common Stock	463	449	447	442	429	410	394	361	333	300
Retained Earnings	7,416	9,261	9,898	13,525	9,268	5,471	3,722	1,830	1,829	1,808
Treasury Stock	-772	-633	-264	-106	-100	-38	-49	-0.22	-0.10	-0.10
Accumulated Other Comprehensive Income / (Loss)	-538	-336	-467	-176	282	-87	-47	739	418	382

This table presents Bio-Rad Laboratories' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Total Assets	9,527	9,364	10,603	9,688	12,610	12,299	11,896	11,978	13,667	13,502	12,058
Total Current Assets	3,037	3,030	3,056	3,056	3,061	3,048	3,147	3,139	2,524	3,158	3,140
Cash & Equivalents	521	488	410	407	433	404	458	390	464	434	518
Short-Term Investments	1,139	1,176	1,212	1,209	1,212	1,203	1,301	1,333	1,387	1,356	1,332
Accounts Receivable	425	453	462	446	445	489	457	492	498	495	432
Inventories, net	790	760	804	804	783	781	776	777	-	719	686
Prepaid Expenses	125	123	133	153	143	140	124	123	121	124	147
Other Current Assets	36	31	28	32	39	26	25	20	48	24	19
Plant, Property, & Equipment, net	529	528	545	534	522	529	511	514	506	499	461
Total Noncurrent Assets	5,962	5,806	7,003	6,098	9,027	8,722	8,238	8,325	9,884	9,845	8,457
Long-Term Investments	4,994	4,839	6,003	5,100	8,018	7,698	7,218	7,311	8,879	8,831	7,459
Goodwill	415	411	415	412	413	414	407	412	408	406	400
Intangible Assets	296	294	307	307	314	321	314	329	328	332	325
Other Noncurrent Operating Assets	257	262	277	280	282	290	298	274	270	276	273
Total Liabilities & Shareholders' Equity	9,527	9,364	10,603	9,688	12,610	12,299	11,896	11,978	13,667	13,502	12,058
Total Liabilities	2,848	2,795	3,116	2,910	3,559	3,558	3,480	3,531	3,904	3,886	3,605
Total Current Liabilities	507	468	498	487	466	523	558	582	590	569	571
Short-Term Debt	1.20	1.20	1.26	0.48	0.49	0.50	0.48	0.48	0.52	0.47	0.45
Accounts Payable	138	122	122	127	103	145	112	150	161	135	143
Current Deferred & Payable Income Tax Liabilities	37	31	44	36	34	36	104	74	51	32	29
Current Employee Benefit Liabilities	157	124	146	132	146	140	155	155	174	195	192
Other Current Liabilities	173	189	185	191	182	202	187	203	203	206	206
Total Noncurrent Liabilities	2,341	2,327	2,618	2,423	3,093	3,035	2,922	2,949	3,314	3,318	3,034
Long-Term Debt	1,201	1,200	1,200	1,200	1,199	1,199	1,199	1,198	1,198	1,198	1,197
Noncurrent Deferred & Payable Income Tax Liabilities	841	818	1,076	878	1,541	1,476	1,370	1,402	1,770	1,770	1,485
Other Noncurrent Operating Liabilities	299	309	342	345	352	361	353	349	346	350	352
Total Equity & Noncontrolling Interests	6,679	6,569	7,488	6,779	9,051	8,741	8,416	8,447	9,764	9,615	8,454
Total Preferred & Common Equity	6,679	6,569	7,488	6,779	9,051	8,741	8,416	8,447	9,764	9,615	8,454
Preferred Stock	0.00	0.00	0.00	0.00	-	0.00	-	-	-	-	-
Total Common Equity	6,679	6,569	7,488	6,779	9,051	8,741	8,417	8,448	9,764	9,615	8,454
Common Stock	476	463	448	475	463	449	439	474	463	447	431
Retained Earnings	7,480	7,416	8,132	7,479	9,645	9,261	8,911	8,805	9,967	9,898	9,047
Treasury Stock	-867	-772	-777	-724	-630	-633	-436	-458	-258	-264	-178
Accumulated Other Comprehensive Income / (Loss)	-410	-538	-315	-451	-426	-336	-498	-373	-408	-467	-845

This table displays calculated financial ratios and metrics derived from Bio-Rad Laboratories' official financial filings.

Metric	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
Period end date	12/31/2024	12/31/2023	12/31/2022	12/31/2021	12/31/2020	12/31/2019	12/31/2018	12/31/2017	12/31/2016	12/31/2015
Growth Metrics	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-3.92%	-4.67%	-4.12%	14.81%	10.12%	0.97%	5.98%	4.45%	2.41%	-7.15%
EBITDA Growth	-19.57%	-14.39%	0.60%	18.09%	75.16%	-52.76%	344.15%	86.05%	-61.24%	9.01%
EBIT Growth	-19.57%	-14.39%	0.60%	18.09%	75.16%	-52.76%	344.15%	86.05%	-61.24%	9.01%
NOPAT Growth	-20.37%	-30.00%	-13.52%	19.54%	82.93%	342.38%	-149.45%	327.61%	-72.08%	23.27%
Net Income Growth	-189.38%	82.43%	-185.27%	11.54%	116.88%	381.02%	199.07%	370.19%	-76.20%	22.95%
EPS Growth	0.00%	0.00%	-100.00%	11.35%	117.04%	381.57%	197.30%	362.50%	-76.28%	21.64%
Operating Cash Flow Growth	21.42%	2,030.11%	-97.37%	14.44%	205,153.33%	-99.90%	1,710.78%	-108.20%	28,980.22%	101.53%
Free Cash Flow Firm Growth	-116.62%	85.35%	-209.41%	-8.08%	96.44%	30.31%	717.28%	-180.69%	-54.91%	19.69%
Invested Capital Growth	101.14%	238.15%	111.90%	-135.94%	-259.50%	-56.36%	-39.52%	17.78%	-5.34%	-7.81%
Revenue Q/Q Growth	-0.53%	-1.81%	-0.09%	-1.92%	6.95%	0.33%	-0.19%	2.36%	0.04%	-1.35%
EBITDA Q/Q Growth	22.65%	-91.07%	104.15%	-90.73%	-52.73%	-53.39%	-66.95%	154.50%	-55.76%	6.00%
EBIT Q/Q Growth	22.65%	-91.07%	104.15%	-90.73%	-52.73%	-53.39%	-66.95%	154.50%	-55.76%	6.00%
NOPAT Q/Q Growth	-12.09%	-6.47%	0.16%	-15.41%	68.38%	536.06%	-151.39%	392.15%	-66.28%	5.91%
Net Income Q/Q Growth	-136.83%	-300.07%	39.75%	-48.42%	96.68%	366.91%	-71.37%	627.20%	-72.45%	6.42%
EPS Q/Q Growth	100.00%	100.00%	100.00%	-36.17%	8.22%	366.53%	-71.39%	653.70%	-72.41%	5.70%
Operating Cash Flow Q/Q Growth	21.41%	2,030.23%	-97.38%	12.67%	289.39%	-99.95%	1,681.86%	-121.26%	866.16%	100.57%
Free Cash Flow Firm Q/Q Growth	-112.08%	-377.54%	19.21%	-31.14%	18.80%	134.50%	-18.26%	-16.96%	14.38%	-1.70%
Invested Capital Q/Q Growth	19.71%	-0.42%	-44.63%	10.60%	-97.65%	-36.39%	-4.69%	3.10%	-5.92%	-0.13%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-
Gross Margin	53.73%	53.42%	55.93%	56.05%	56.48%	54.38%	53.43%	54.98%	55.05%	55.54%
EBITDA Margin	14.15%	16.91%	18.82%	17.94%	17.44%	10.97%	23.44%	5.59%	3.14%	8.30%
Operating Margin	10.48%	12.65%	17.22%	17.12%	16.55%	9.93%	-4.51%	5.52%	2.69%	8.26%
EBIT Margin	14.15%	16.91%	18.82%	17.94%	17.44%	10.97%	23.44%	5.59%	3.14%	8.30%
Profit (Net Income) Margin	-71.86%	-23.86%	-129.45%	145.57%	149.83%	76.08%	15.97%	5.66%	1.26%	5.41%
Tax Burden Percent	78.73%	74.97%	77.11%	78.07%	77.56%	77.78%	71.32%	124.99%	62.56%	74.90%
Interest Burden Percent	-644.96%	-188.24%	-891.79%	1,039.19%	1,107.55%	891.91%	95.53%	80.95%	64.00%	87.05%
Effective Tax Rate	0.00%	0.00%	0.00%	21.93%	22.44%	22.22%	28.68%	-24.99%	37.44%	25.10%
Return on Invested Capital (ROIC)	19.85%	57.93%	0.00%	0.00%	0.00%	26.08%	-5.82%	10.22%	2.53%	8.47%
ROIC Less NNEP Spread (ROIC-NNEP)	50.16%	67.90%	0.00%	0.00%	0.00%	-11.52%	-25.70%	12.29%	3.30%	10.28%
Return on Net Nonoperating Assets (RNNOA)	-43.94%	-64.88%	0.00%	0.00%	0.00%	9.90%	16.34%	-5.79%	-1.51%	-3.80%
Return on Equity (ROE)	-24.09%	-6.94%	-31.14%	36.11%	48.79%	35.98%	10.52%	4.44%	1.03%	4.67%
Cash Return on Invested Capital (CROIC)	-47.32%	-50.77%	-759.35%	0.00%	0.00%	104.55%	43.43%	-6.11%	8.01%	16.60%
Operating Return on Assets (OROA)	3.35%	3.50%	3.37%	3.41%	4.23%	3.72%	10.86%	2.97%	1.72%	4.75%
Return on Assets (ROA)	-17.03%	-4.94%	-23.18%	27.65%	36.36%	25.83%	7.40%	3.01%	0.69%	3.10%
Return on Common Equity (ROCE)	-24.09%	-6.94%	-31.14%	36.11%	48.79%	35.98%	10.52%	4.44%	1.03%	4.67%
Return on Equity Simple (ROE_SIMPLE)	-28.07%	-7.29%	-37.73%	31.09%	38.61%	30.56%	9.09%	4.17%	1.01%	4.39%
Net Operating Profit after Tax (NOPAT)	188	236	338	391	327	179	-74	149	35	125
NOPAT Margin	7.34%	8.85%	12.06%	13.37%	12.84%	7.73%	-3.22%	6.90%	1.69%	6.18%
Net Nonoperating Expense Percent (NNEP)	-30.31%	-9.96%	-32.13%	29.96%	43.92%	37.60%	19.88%	-2.07%	-0.76%	-1.81%
Return On Investment Capital (ROIC_SIMPLE)	2.42%	2.38%	3.12%	-	-	-	-	-	-	-
Cost of Revenue to Revenue	46.27%	46.58%	44.07%	43.95%	43.52%	45.62%	46.57%	45.02%	44.95%	44.46%
SG&A Expenses to Revenue	31.72%	31.51%	29.54%	30.01%	31.38%	35.67%	36.46%	37.35%	39.39%	37.73%
R&D to Revenue	11.53%	9.26%	9.17%	8.92%	8.55%	8.77%	8.70%	11.58%	9.95%	9.56%
Operating Expenses to Revenue	43.25%	40.77%	38.71%	38.93%	39.93%	44.44%	57.94%	49.46%	52.35%	47.29%
Earnings before Interest and Taxes (EBIT)	363	452	528	524	444	254	537	121	65	168
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	363	452	528	524	444	254	537	121	65	168
Valuation Ratios	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.40	1.08	1.30	1.65	1.76	1.92	1.73	2.42	2.09	1.63
Price to Tangible Book Value (P/TBV)	1.57	1.18	1.41	1.73	1.85	2.07	1.90	3.16	2.78	2.28
Price to Revenue (P/Rev)	3.58	3.52	4.48	7.73	6.83	4.79	3.04	3.29	2.60	2.01
Price to Earnings (P/E)	0.00	0.00	0.00	5.31	4.56	6.30	19.03	58.11	207.11	37.20
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	18.82%	21.93%	15.88%	5.25%	1.72%	0.48%	2.69%
Enterprise Value to Invested Capital (EV/IC)	3.07	2.06	16.70	0.00	0.00	13.85	4.08	3.65	3.10	2.11
Enterprise Value to Revenue (EV/Rev)	1.52	0.49	1.11	2.52	2.69	2.49	1.70	2.66	2.00	1.48
Enterprise Value to EBITDA (EV/EBITDA)	10.72	2.88	5.90	14.02	15.42	22.74	7.25	47.60	63.82	17.83
Enterprise Value to EBIT (EV/EBIT)	10.72	2.88	5.90	14.02	15.42	22.74	7.25	47.60	63.82	17.83
Enterprise Value to NOPAT (EV/NOPAT)	20.69	5.50	9.21	18.83	20.95	32.28	0.00	38.58	118.90	23.92
Enterprise Value to Operating Cash Flow (EV/OCF)	8.56	3.47	176.81	10.98	11.70	20,230.28	13.63	0.00	19.18	4,020.67
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	5.69	4.87	8.05	7.08	0.00	37.56	12.21
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.18	0.14	0.12	0.00	0.00	0.08	0.11	0.15	0.17	0.17
Long-Term Debt to Equity	0.18	0.14	0.12	0.00	0.00	0.00	0.11	0.15	0.17	0.17
Financial Leverage	-0.88	-0.96	-1.06	-1.09	-1.02	-0.86	-0.64	-0.47	-0.46	-0.37
Leverage Ratio	1.41	1.41	1.34	1.31	1.34	1.39	1.42	1.47	1.49	1.51
Compound Leverage Factor	-9.13	-2.65	-11.98	13.57	14.86	12.43	1.36	1.19	0.95	1.31
Debt to Total Capital	15.46%	12.07%	11.08%	0.08%	0.14%	7.10%	9.85%	12.93%	14.42%	14.85%
Short-Term Debt to Total Capital	0.02%	0.01%	0.00%	0.00%	0.02%	6.88%	0.01%	0.01%	0.01%	0.01%
Long-Term Debt to Total Capital	15.45%	12.06%	11.08%	0.08%	0.12%	0.22%	9.84%	12.91%	14.41%	14.84%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.12%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.54%	87.93%	88.92%	99.92%	99.86%	92.90%	90.15%	87.07%	85.58%	85.15%
Debt to EBITDA	3.31	2.66	2.27	0.02	0.03	1.73	0.82	3.60	6.69	2.59
Net Debt to EBITDA	-14.60	-17.96	-17.87	-29.09	-23.74	-20.98	-5.71	-11.20	-19.10	-6.42
Long-Term Debt to EBITDA	3.31	2.66	2.27	0.02	0.03	0.05	0.82	3.60	6.69	2.59
Debt to NOPAT	6.38	5.07	3.55	0.03	0.04	2.46	-5.96	2.92	12.47	3.48
Net Debt to NOPAT	-28.16	-34.30	-27.91	-39.04	-32.27	-29.77	41.61	-9.08	-35.58	-8.62
Long-Term Debt to NOPAT	6.37	5.07	3.55	0.03	0.04	0.08	-5.96	2.92	12.46	3.47
Altman Z-Score	3.81	3.23	3.53	4.71	4.82	4.49	4.61	4.79	4.23	3.81
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-
Current Ratio	6.48	5.83	5.55	2.92	3.39	2.41	4.49	3.93	3.91	4.03
Quick Ratio	4.53	4.01	4.02	1.90	2.23	1.64	2.74	2.43	2.57	2.67
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-449	-207	-1,415	1,293	1,407	716	550	-89	110	245
Operating Cash Flow to CapEx	275.05%	239.55%	15.63%	500.74%	539.17%	0.29%	227.47%	-15.41%	153.20%	0.64%
Free Cash Flow to Firm to Interest Expense	-9.18	-4.20	-37.13	833.69	64.35	30.58	22.94	-3.87	4.72	11.28
Operating Cash Flow to Interest Expense	9.31	7.59	0.46	431.63	26.76	0.01	11.91	-0.77	9.24	0.03
Operating Cash Flow Less CapEx to Interest Expense	5.92	4.42	-2.49	345.44	21.80	-4.19	6.68	-5.77	3.21	-5.33
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.24	0.21	0.18	0.19	0.24	0.34	0.46	0.53	0.55	0.57
Accounts Receivable Turnover	5.45	5.43	6.10	6.93	6.43	6.04	5.34	5.16	5.42	5.25
Inventory Turnover	1.54	1.66	1.91	2.15	1.88	1.85	1.81	1.74	1.83	1.87
Fixed Asset Turnover	4.86	5.20	5.55	5.83	5.14	4.59	4.57	4.40	4.47	4.66
Accounts Payable Turnover	8.90	8.90	8.92	9.13	8.99	9.19	8.28	7.25	7.28	7.15
Days Sales Outstanding (DSO)	66.95	67.20	59.80	52.64	56.77	60.39	68.34	70.73	67.40	69.51
Days Inventory Outstanding (DIO)	236.73	219.98	190.87	169.72	193.79	196.89	201.73	210.15	199.27	195.40
Days Payable Outstanding (DPO)	41.01	41.01	40.93	39.98	40.61	39.71	44.10	50.35	50.15	51.02
Cash Conversion Cycle (CCC)	262.66	246.17	209.74	182.38	209.96	217.57	225.97	230.53	216.52	213.88
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,267	630	186	-1,566	-664	416	954	1,577	1,339	1,414
Invested Capital Turnover	2.71	6.54	-4.06	-2.62	-20.56	3.38	1.81	1.48	1.50	1.37
Increase / (Decrease) in Invested Capital	637	444	1,753	-902	-1,080	-538	-623	238	-75	-120
Enterprise Value (EV)	3,895	1,299	3,112	7,354	6,846	5,766	3,891	5,750	4,145	2,987
Market Capitalization	9,197	9,411	12,541	22,605	17,389	11,077	6,958	7,104	5,385	4,063
Book Value per Share	$234.65	$299.92	$322.40	$457.42	$331.20	$192.25	$134.18	$98.45	$87.31	$84.98
Tangible Book Value per Share	$209.50	$274.73	$297.63	$437.32	$314.73	$178.57	$122.40	$75.60	$65.69	$60.76
Total Capital	7,771	9,941	10,813	13,696	9,894	6,195	4,460	3,365	3,014	2,925
Total Debt	1,202	1,200	1,198	11	14	440	439	435	435	434
Total Long-Term Debt	1,200	1,199	1,198	11	12	14	439	435	434	434
Net Debt	-5,302	-8,111	-9,429	-15,251	-10,544	-5,319	-3,067	-1,353	-1,240	-1,076
Capital Expenditures (CapEx)	166	157	113	134	108	98	126	115	141	116
Debt-free, Cash-free Net Working Capital (DFCFNWC)	899	913	794	435	513	581	723	714	530	546
Debt-free Net Working Capital (DFNWC)	2,564	2,526	2,590	1,310	1,510	1,701	1,573	1,474	1,374	1,337
Net Working Capital (NWC)	2,563	2,526	2,589	1,310	1,508	1,275	1,573	1,474	1,373	1,336
Net Nonoperating Expense (NNE)	2,033	874	3,965	-3,864	-3,487	-1,580	-439	27	8.86	16
Net Nonoperating Obligations (NNO)	-5,302	-8,111	-9,429	-15,251	-10,544	-5,339	-3,067	-1,353	-1,240	-1,076
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	35.04%	34.19%	28.32%	14.87%	20.17%	25.12%	31.57%	33.05%	25.60%	27.04%
Debt-free Net Working Capital to Revenue	99.89%	94.56%	92.42%	44.83%	59.32%	73.58%	68.72%	68.25%	66.41%	66.18%
Net Working Capital to Revenue	99.84%	94.55%	92.40%	44.81%	59.25%	55.14%	68.69%	68.23%	66.40%	66.17%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	($65.36)	($21.82)	($121.79)	$142.33	$127.86	$58.93	$12.25	$4.12	$0.96	$3.87
Adjusted Weighted Average Basic Shares Outstanding	28.21M	29.21M	29.79M	29.83M	29.77M	29.84M	29.84M	29.66M	29.44M	29.19M
Adjusted Diluted Earnings per Share	$0.00	($21.82)	($121.79)	$140.56	$126.20	$58.27	$12.10	$4.07	$0.95	$3.85
Adjusted Weighted Average Diluted Shares Outstanding	28.21M	29.21M	29.79M	30.21M	30.16M	30.18M	30.23M	30.03M	29.65M	29.41M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	28.01M	28.52M	29.60M	29.93M	29.84M	29.93M	29.80M	0.00	29.58M	29.36M
Normalized Net Operating Profit after Tax (NOPAT)	188	236	338	391	327	179	135	92	74	125
Normalized NOPAT Margin	7.34%	8.85%	12.06%	13.37%	12.84%	7.73%	5.89%	4.24%	3.57%	6.18%
Pre Tax Income Margin	-91.27%	-31.82%	-167.88%	186.45%	193.19%	97.81%	22.39%	4.53%	2.01%	7.22%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.43	9.14	13.85	338.08	20.31	10.83	22.39	5.25	2.78	7.72
NOPAT to Interest Expense	3.85	4.79	8.87	251.86	14.95	7.63	-3.08	6.48	1.49	5.76
EBIT Less CapEx to Interest Expense	4.04	5.97	10.89	251.88	15.35	6.62	17.16	0.25	-3.25	2.36
NOPAT Less CapEx to Interest Expense	0.47	1.62	5.91	165.66	9.98	3.43	-8.31	1.48	-4.54	0.40
Payout Ratios	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-11.04%	-67.27%	-5.95%	1.18%	2.62%	1.59%	13.38%	2.39%	0.00%	0.00%

This table displays calculated financial ratios and metrics derived from Bio-Rad Laboratories' official financial filings.

Metric	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022
Period end date	3/31/2025	12/31/2024	9/30/2024	6/30/2024	3/31/2024	12/31/2023	9/30/2023	6/30/2023	3/31/2023	12/31/2022	9/30/2022
Growth Metrics	-	-	-	-	-	-	-	-	-	-	-
Revenue Growth	-4.16%	-2.00%	2.79%	-6.26%	-9.75%	-6.73%	-7.15%	-1.45%	-3.32%	-0.35%	-8.87%
EBITDA Growth	-81.05%	3.96%	484.48%	-86.42%	418.04%	-73.11%	176.41%	-23.03%	102.23%	190.56%	-103.90%
EBIT Growth	-81.05%	3.96%	484.48%	-86.42%	418.04%	-73.11%	176.41%	-23.03%	102.23%	190.56%	-103.90%
NOPAT Growth	-47.84%	-47.53%	-30.67%	13.26%	-30.56%	-13.53%	6.39%	-27.08%	-50.89%	9.06%	-45.98%
Net Income Growth	-83.33%	-304.67%	514.71%	-86.32%	456.71%	-57.75%	165.27%	-25.63%	102.05%	152.88%	-104.14%
EPS Growth	-82.97%	17.37%	541.21%	-92.62%	479.74%	-71.50%	166.42%	0.00%	102.06%	327.63%	-104.22%
Operating Cash Flow Growth	0.89%	21.42%	-0.99%	0.99%	0.00%	2,030.11%	0.00%	53.39%	-100.00%	-97.38%	0.00%
Free Cash Flow Firm Growth	41.54%	-63.00%	-67.02%	-19.70%	-669.37%	77.99%	88.84%	56.43%	145.27%	-268.80%	-231.42%
Invested Capital Growth	111.00%	101.14%	67.31%	107.43%	210.48%	238.15%	88.03%	931.51%	-35.57%	111.90%	119.21%
Revenue Q/Q Growth	-12.30%	2.73%	1.76%	4.53%	-10.33%	7.75%	-7.19%	0.63%	-7.32%	7.26%	-1.49%
EBITDA Q/Q Growth	-94.58%	101.43%	131.50%	-651.11%	-70.27%	1,032.45%	110.05%	-1,631.49%	-98.46%	3,318.23%	83.82%
EBIT Q/Q Growth	-94.58%	101.43%	131.50%	-651.11%	-70.27%	1,032.45%	110.05%	-1,631.49%	-98.46%	3,318.23%	83.82%
NOPAT Q/Q Growth	-55.46%	-16.45%	-31.21%	103.27%	-55.08%	10.40%	12.36%	24.64%	-44.08%	35.84%	-22.98%
Net Income Q/Q Growth	108.94%	-209.59%	130.16%	-664.05%	9.78%	229.14%	109.14%	-1,785.35%	-91.67%	608.43%	82.40%
EPS Q/Q Growth	-94.20%	69.11%	130.61%	-666.99%	13.89%	823.90%	109.19%	-1,806.47%	160.89%	2,252.92%	0.00%
Operating Cash Flow Q/Q Growth	-104.88%	1,853.56%	200.00%	0.00%	-100.00%	1,492.95%	200.00%	0.00%	-100.00%	0.00%	0.00%
Free Cash Flow Firm Q/Q Growth	-5.16%	-58.19%	35.04%	45.90%	-193.25%	-62.10%	53.45%	-357.36%	111.33%	17.78%	-81.73%
Invested Capital Q/Q Growth	-3.20%	19.71%	-15.84%	116.34%	-7.70%	-0.42%	4.34%	215.23%	-382.45%	-44.63%	472.38%
Profitability Metrics	-	-	-	-	-	-	-	-	-	-	-
Gross Margin	52.27%	51.22%	54.78%	55.62%	53.37%	53.78%	53.10%	53.22%	53.55%	54.37%	54.72%
EBITDA Margin	16.30%	263.69%	134.49%	-434.47%	82.41%	248.56%	23.65%	-218.48%	14.36%	862.27%	-28.74%
Operating Margin	4.05%	8.74%	9.92%	15.90%	7.32%	13.99%	14.39%	13.16%	9.15%	16.25%	13.90%
EBIT Margin	16.30%	263.69%	134.49%	-434.47%	82.41%	248.56%	23.65%	-218.48%	14.36%	862.27%	-28.74%
Profit (Net Income) Margin	10.93%	-107.24%	100.53%	-339.16%	62.85%	51.35%	16.81%	-170.64%	10.19%	113.36%	-23.91%
Tax Burden Percent	76.74%	78.75%	75.81%	77.72%	78.18%	81.64%	77.50%	77.46%	81.30%	75.85%	78.53%
Interest Burden Percent	87.42%	-51.64%	98.61%	100.44%	97.56%	25.30%	91.71%	100.83%	87.30%	17.33%	105.96%
Effective Tax Rate	23.26%	0.00%	24.19%	0.00%	21.82%	18.36%	22.50%	0.00%	18.70%	24.15%	0.00%
Return on Invested Capital (ROIC)	8.73%	16.55%	22.95%	30.59%	540.51%	74.77%	62.60%	76.68%	0.00%	0.00%	0.00%
ROIC Less NNEP Spread (ROIC-NNEP)	8.07%	27.83%	14.45%	64.07%	536.79%	71.67%	62.15%	91.35%	0.00%	0.00%	0.00%
Return on Net Nonoperating Assets (RNNOA)	-7.15%	-24.38%	-12.91%	-56.23%	-535.22%	-68.48%	-58.58%	-87.85%	0.00%	0.00%	0.00%
Return on Equity (ROE)	1.59%	-7.83%	10.04%	-25.63%	5.29%	6.29%	4.02%	-11.17%	-1.92%	-31.14%	-50.62%
Cash Return on Invested Capital (CROIC)	-52.17%	-47.32%	-25.03%	-44.92%	-151.91%	-50.77%	-8.96%	-87.86%	0.00%	-759.35%	-520.42%
Operating Return on Assets (OROA)	3.74%	62.48%	30.85%	-102.77%	16.34%	51.47%	5.37%	-49.06%	2.85%	154.39%	-5.04%
Return on Assets (ROA)	2.51%	-25.41%	23.06%	-80.23%	12.46%	10.63%	3.82%	-38.32%	2.02%	20.30%	-4.19%
Return on Common Equity (ROCE)	1.59%	-7.83%	10.04%	-25.63%	5.29%	6.29%	4.02%	-11.17%	-1.92%	-31.14%	-50.62%
Return on Equity Simple (ROE_SIMPLE)	-32.40%	0.00%	-10.40%	-19.56%	-3.56%	0.00%	-1.89%	-5.07%	-1.96%	0.00%	-71.22%
Net Operating Profit after Tax (NOPAT)	18	41	49	71	35	78	70	63	50	90	66
NOPAT Margin	3.11%	6.12%	7.52%	11.13%	5.72%	11.42%	11.15%	9.21%	7.44%	12.32%	9.73%
Net Nonoperating Expense Percent (NNEP)	0.66%	-11.28%	8.50%	-33.48%	3.72%	3.10%	0.45%	-14.67%	0.18%	5.98%	-1.82%
Return On Investment Capital (ROIC_SIMPLE)	0.23%	0.53%	-	-	-	0.78%	-	-	-	0.83%	-
Cost of Revenue to Revenue	47.73%	48.78%	45.22%	44.38%	46.63%	46.22%	46.90%	46.78%	46.45%	45.63%	45.28%
SG&A Expenses to Revenue	35.67%	30.56%	30.85%	30.50%	35.18%	30.41%	31.83%	30.51%	33.32%	29.06%	31.01%
R&D to Revenue	12.56%	11.93%	14.01%	9.23%	10.87%	9.38%	6.89%	9.55%	11.07%	9.07%	9.81%
Operating Expenses to Revenue	48.22%	42.49%	44.86%	39.72%	46.05%	39.79%	38.72%	40.06%	44.40%	38.13%	40.82%
Earnings before Interest and Taxes (EBIT)	95	1,760	874	-2,774	503	1,693	150	-1,488	97	6,297	-196
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)	95	1,760	874	-2,774	503	1,693	150	-1,488	97	6,297	-196
Valuation Ratios	-	-	-	-	-	-	-	-	-	-	-
Price to Book Value (P/BV)	1.02	1.40	1.25	1.15	1.09	1.08	1.24	1.33	1.45	1.30	1.47
Price to Tangible Book Value (P/TBV)	1.14	1.57	1.38	1.29	1.18	1.18	1.35	1.46	1.57	1.41	1.60
Price to Revenue (P/Rev)	2.68	3.58	3.61	3.04	3.79	3.52	3.83	4.05	5.10	4.48	4.42
Price to Earnings (P/E)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Dividend Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Earnings Yield	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Enterprise Value to Invested Capital (EV/IC)	1.12	3.07	2.74	1.80	2.40	2.06	4.17	5.58	0.00	16.70	12.69
Enterprise Value to Revenue (EV/Rev)	0.54	1.52	1.12	0.89	0.54	0.49	0.97	1.22	1.67	1.11	1.52
Enterprise Value to EBITDA (EV/EBITDA)	0.00	10.72	9.78	0.00	1.63	2.88	0.52	0.72	0.93	5.90	0.00
Enterprise Value to EBIT (EV/EBIT)	0.00	10.72	9.78	0.00	1.63	2.88	0.52	0.72	0.93	5.90	0.00
Enterprise Value to NOPAT (EV/NOPAT)	7.89	20.69	13.52	9.75	6.21	5.50	10.44	13.25	16.65	9.21	12.66
Enterprise Value to Operating Cash Flow (EV/OCF)	3.01	8.56	7.72	6.05	3.72	3.47	149.94	0.00	0.00	176.81	6.36
Enterprise Value to Free Cash Flow (EV/FCFF)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	11.13	0.00	0.00
Leverage & Solvency	-	-	-	-	-	-	-	-	-	-	-
Debt to Equity	0.18	0.18	0.16	0.18	0.13	0.14	0.14	0.14	0.12	0.12	0.14
Long-Term Debt to Equity	0.18	0.18	0.16	0.18	0.13	0.14	0.14	0.14	0.12	0.12	0.14
Financial Leverage	-0.89	-0.88	-0.89	-0.88	-1.00	-0.96	-0.94	-0.96	-1.05	-1.06	-1.06
Leverage Ratio	1.41	1.41	1.41	1.42	1.40	1.41	1.42	1.42	1.41	1.34	1.35
Compound Leverage Factor	1.23	-0.73	1.40	1.43	1.36	0.36	1.30	1.43	1.23	0.23	1.43
Debt to Total Capital	15.25%	15.46%	13.83%	15.04%	11.70%	12.07%	12.47%	12.43%	10.93%	11.08%	12.41%
Short-Term Debt to Total Capital	0.02%	0.02%	0.01%	0.01%	0.00%	0.01%	0.01%	0.00%	0.00%	0.00%	0.00%
Long-Term Debt to Total Capital	15.23%	15.45%	13.81%	15.04%	11.70%	12.06%	12.47%	12.42%	10.93%	11.08%	12.41%
Preferred Equity to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Noncontrolling Interests to Total Capital	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Common Equity to Total Capital	84.75%	84.54%	86.17%	84.96%	88.30%	87.93%	87.54%	87.58%	89.07%	88.92%	87.59%
Debt to EBITDA	-26.83	3.31	4.06	-2.80	1.40	2.66	0.24	0.25	0.24	2.27	-0.09
Net Debt to EBITDA	121.71	-14.60	-21.71	12.89	-9.87	-17.96	-1.54	-1.66	-1.91	-17.87	0.64
Long-Term Debt to EBITDA	-26.80	3.31	4.05	-2.80	1.40	2.66	0.24	0.25	0.24	2.27	-0.09
Debt to NOPAT	6.92	6.38	5.61	5.16	5.35	5.07	4.74	4.69	4.30	3.55	3.55
Net Debt to NOPAT	-31.40	-28.16	-30.02	-23.72	-37.74	-34.30	-30.79	-30.70	-34.22	-27.91	-24.07
Long-Term Debt to NOPAT	6.91	6.37	5.60	5.16	5.34	5.07	4.74	4.69	4.30	3.55	3.55
Altman Z-Score	3.16	4.31	3.67	2.33	3.32	3.56	3.38	3.01	3.60	4.94	3.55
Noncontrolling Interest Sharing Ratio	0.00%	0.00%	-0.01%	-0.01%	0.00%	0.00%	-0.01%	-0.01%	0.00%	0.00%	0.00%
Liquidity Ratios	-	-	-	-	-	-	-	-	-	-	-
Current Ratio	5.99	6.48	6.14	6.28	6.57	5.83	5.64	5.39	4.28	5.55	5.50
Quick Ratio	4.12	4.53	4.19	4.23	4.48	4.01	3.97	3.80	3.99	4.02	4.00
Cash Flow Metrics	-	-	-	-	-	-	-	-	-	-	-
Free Cash Flow to Firm (FCFF)	-627	-596	-377	-580	-1,073	-366	-226	-485	188	-1,663	-2,022
Operating Cash Flow to CapEx	-64.53%	1,059.52%	58.00%	-55.20%	0.00%	889.04%	53.48%	-68.02%	0.00%	50.68%	0.00%
Free Cash Flow to Firm to Interest Expense	-52.26	-48.94	-30.97	-47.32	-87.37	-29.69	-18.21	-39.28	15.27	-142.48	-173.38
Operating Cash Flow to Interest Expense	-1.85	37.36	1.91	-1.90	0.00	30.43	1.90	-1.91	0.00	1.51	0.00
Operating Cash Flow Less CapEx to Interest Expense	-4.72	33.83	-1.39	-5.34	-3.27	27.00	-1.65	-4.71	-2.90	-1.47	0.00
Efficiency Ratios	-	-	-	-	-	-	-	-	-	-	-
Asset Turnover	0.23	0.24	0.23	0.24	0.20	0.21	0.23	0.22	0.20	0.18	0.18
Accounts Receivable Turnover	5.84	5.45	5.61	5.47	5.52	5.43	6.12	5.88	5.78	6.10	6.60
Inventory Turnover	1.50	1.54	1.49	1.49	0.00	1.66	1.73	1.78	0.00	1.91	1.94
Fixed Asset Turnover	4.84	4.86	4.88	4.89	5.06	5.20	5.59	5.62	5.60	5.55	5.98
Accounts Payable Turnover	9.82	8.90	10.06	8.54	9.21	8.90	9.92	8.28	7.78	8.92	8.86
Days Sales Outstanding (DSO)	62.45	66.95	65.03	66.74	66.06	67.20	59.69	62.08	63.20	59.80	55.31
Days Inventory Outstanding (DIO)	242.92	236.73	245.03	244.52	0.00	219.98	211.26	205.30	0.00	190.87	188.21
Days Payable Outstanding (DPO)	37.15	41.01	36.29	42.74	39.62	41.01	36.80	44.07	46.89	40.93	41.21
Cash Conversion Cycle (CCC)	268.22	262.66	273.76	268.51	26.44	246.17	234.15	223.31	16.31	209.74	202.31
Capital & Investment Metrics	-	-	-	-	-	-	-	-	-	-	-
Invested Capital	1,227	1,267	1,059	1,258	581	630	633	606	-526	186	336
Invested Capital Turnover	2.81	2.71	3.05	2.75	94.46	6.54	5.61	8.33	-6.08	-4.06	-3.96
Increase / (Decrease) in Invested Capital	645	637	426	651	1,108	444	296	548	-138	1,753	2,088
Enterprise Value (EV)	1,370	3,895	2,896	2,269	1,394	1,299	2,639	3,385	4,640	3,112	4,271
Market Capitalization	6,822	9,197	9,325	7,790	9,864	9,411	10,422	11,225	14,177	12,541	12,388
Book Value per Share	$238.46	$234.65	$268.66	$237.65	$317.38	$299.92	$289.49	$285.32	$329.90	$322.40	$284.66
Tangible Book Value per Share	$213.08	$209.50	$242.74	$212.43	$291.91	$274.73	$264.69	$260.32	$305.05	$297.63	$260.25
Total Capital	7,881	7,771	8,689	7,979	10,251	9,941	9,615	9,646	10,962	10,813	9,651
Total Debt	1,202	1,202	1,201	1,200	1,200	1,200	1,199	1,199	1,199	1,198	1,198
Total Long-Term Debt	1,201	1,200	1,200	1,200	1,199	1,199	1,199	1,198	1,198	1,198	1,197
Net Debt	-5,453	-5,302	-6,429	-5,521	-8,470	-8,111	-7,784	-7,841	-9,537	-9,429	-8,117
Capital Expenditures (CapEx)	34	43	40	42	40	42	44	35	36	35	28
Debt-free, Cash-free Net Working Capital (DFCFNWC)	871	899	931	948	944	913	825	829	78	794	714
Debt-free Net Working Capital (DFNWC)	2,531	2,564	2,559	2,570	2,595	2,526	2,589	2,557	1,935	2,590	2,570
Net Working Capital (NWC)	2,530	2,563	2,558	2,569	2,595	2,526	2,589	2,557	1,935	2,589	2,569
Net Nonoperating Expense (NNE)	-46	757	-604	2,237	-349	-272	-36	1,225	-19	-738	229
Net Nonoperating Obligations (NNO)	-5,453	-5,302	-6,429	-5,521	-8,470	-8,111	-7,784	-7,841	-10,290	-9,429	-8,117
Total Depreciation and Amortization (D&A)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Debt-free, Cash-free Net Working Capital to Revenue	34.27%	35.04%	36.08%	37.00%	36.24%	34.19%	30.31%	29.94%	2.81%	28.32%	25.47%
Debt-free Net Working Capital to Revenue	99.61%	99.89%	99.18%	100.28%	99.62%	94.56%	95.17%	92.36%	69.64%	92.42%	91.63%
Net Working Capital to Revenue	99.56%	99.84%	99.13%	100.26%	99.60%	94.55%	95.16%	92.34%	69.62%	92.40%	91.61%
Earnings Adjustments	-	-	-	-	-	-	-	-	-	-	-
Adjusted Basic Earnings per Share	$2.29	($25.93)	$23.37	($76.26)	$13.46	$11.79	$3.65	($39.59)	$2.33	$27.24	($5.52)
Adjusted Weighted Average Basic Shares Outstanding	27.94M	28.21M	27.95M	28.40M	28.52M	29.21M	29.10M	29.36M	29.60M	29.79M	29.73M
Adjusted Diluted Earnings per Share	$2.29	$39.47	$23.34	($76.26)	$13.45	$33.63	$3.64	$0.00	$2.32	$117.98	($5.52)
Adjusted Weighted Average Diluted Shares Outstanding	27.96M	28.21M	27.99M	28.40M	28.54M	29.21M	29.22M	29.36M	29.75M	29.79M	29.73M
Adjusted Basic & Diluted Earnings per Share	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00	$0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding	27.21M	28.01M	28.00M	27.87M	28.52M	28.52M	29.15M	29.08M	29.61M	29.60M	29.82M
Normalized Net Operating Profit after Tax (NOPAT)	18	41	49	71	35	78	70	63	50	90	66
Normalized NOPAT Margin	3.11%	6.12%	7.52%	11.13%	5.72%	11.42%	11.15%	9.21%	7.44%	12.32%	9.73%
Pre Tax Income Margin	14.25%	-136.17%	132.61%	-436.40%	80.40%	62.90%	21.69%	-220.29%	12.53%	149.45%	-30.45%
Debt Service Ratios	-	-	-	-	-	-	-	-	-	-	-
EBIT to Interest Expense	7.95	144.45	71.78	-226.19	41.00	137.40	12.06	-120.56	7.88	539.60	-16.78
NOPAT to Interest Expense	1.52	3.35	4.01	5.79	2.85	6.32	5.69	5.08	4.08	7.71	5.68
EBIT Less CapEx to Interest Expense	5.08	140.92	68.48	-229.63	37.73	133.98	8.51	-123.36	4.98	536.63	-19.14
NOPAT Less CapEx to Interest Expense	-1.35	-0.18	0.71	2.35	-0.42	2.89	2.14	2.28	1.18	4.74	3.32
Payout Ratios	-	-	-	-	-	-	-	-	-	-	-
Dividend Payout Ratio	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%
Augmented Payout Ratio	-13.90%	-11.04%	-51.83%	-24.67%	-134.47%	-67.27%	-200.51%	-69.59%	0.00%	-5.95%	-2.08%

Frequently Asked Questions About Bio-Rad Laboratories' Financials

When does Bio-Rad Laboratories's financial year end?

According to the most recent income statement we have on file, Bio-Rad Laboratories' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Bio-Rad Laboratories' net income changed over the last 9 years?

Bio-Rad Laboratories' net income appears to be on a downward trend, with a most recent value of -$1.84 billion in 2024, falling from $109.24 million in 2015. The previous period was -$637.30 million in 2023.

What is Bio-Rad Laboratories's operating income?

Bio-Rad Laboratories's total operating income in 2024 was $269 million, based on the following breakdown:

Total Gross Profit: $1.38 billion
Total Operating Expenses: $1.11 billion

How has Bio-Rad Laboratories revenue changed over the last 9 years?

Over the last 9 years, Bio-Rad Laboratories' total revenue changed from $2.02 billion in 2015 to $2.57 billion in 2024, a change of 27.1%.

How much debt does Bio-Rad Laboratories have?

Bio-Rad Laboratories' total liabilities were at $2.79 billion at the end of 2024, a 21.4% decrease from 2023, and a 129.2% increase since 2015.

How much cash does Bio-Rad Laboratories have?

In the past 9 years, Bio-Rad Laboratories' cash and equivalents has ranged from $383.82 million in 2017 to $662.21 million in 2020, and is currently $488.10 million as of their latest financial filing in 2024.

How has Bio-Rad Laboratories' book value per share changed over the last 9 years?

Over the last 9 years, Bio-Rad Laboratories' book value per share changed from 84.98 in 2015 to 234.65 in 2024, a change of 176.1%.

Related Companies

This page (NYSE:BIO.B) was last updated on 5/25/2025 by MarketBeat.com Staff

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Bio-Rad Laboratories (BIO.B) Financials

Frequently Asked Questions About Bio-Rad Laboratories' Financials

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Bio-Rad Laboratories (BIO.B) Financials

Annual Income Statements for Bio-Rad Laboratories

Quarterly Income Statements for Bio-Rad Laboratories

Annual Cash Flow Statements for Bio-Rad Laboratories

Quarterly Cash Flow Statements for Bio-Rad Laboratories

Annual Balance Sheets for Bio-Rad Laboratories

Quarterly Balance Sheets for Bio-Rad Laboratories

Annual Metrics And Ratios for Bio-Rad Laboratories

Quarterly Metrics And Ratios for Bio-Rad Laboratories

Frequently Asked Questions About Bio-Rad Laboratories' Financials

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools